6-chloropurine riboside | 2004-06-0

• 物质功能分类: 生物化工 - 核苷类药物 - 核苷酸及其类似物
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 6-chloropurine riboside
• 英文别名: 6-chloro-9β-D-ribofuranosyl-9H-purine；6-Chloro-9-ribofuranosyl-9H-purine；(3R,4S,5R)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 2004-06-0
• 化学式: C₁₀H₁₁ClN₄O₄
• 分子量: 286.675
• InChiKey: XHRJGHCQQPETRH-VTHZCTBJSA-N

物化性质

• 熔点：
  158-162 °C (dec.)(lit.)
• 沸点：
  614.8±65.0 °C(Predicted)
• 密度：
  1.7303 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S22,S24/25
• 危险类别码：
  R36/37/38
• 海关编码：
  2942000000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-chloropurine riboside 在 咪唑 、 三丁基氯化锡 、 2,2,6,6-tetramethylpiperidinyl-lithium 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 1-((3R,4R,5R)-2-{6-chloro-2-[1-benzylpyrazol-4-yl]purin-9-yl}-4-(1,1,2,2-tetramethyl-1-silapropoxy)-5-[(1,1,2,2-tetramethyl-1-silapropoxy)methyl]oxolan-3-yloxy)-1,1,2,2-tetramethyl-1-silapropane
  参考文献：
  名称：

  2-Pyrazolyl-N⁶-Substituted Adenosine Derivatives as High Affinity and Selective Adenosine A₃ Receptor Agonists

  摘要：

  We describe the synthesis of new high affinity and selective A(3)-adenosine receptor (A(3)-AdoR) agonists. Introduction of a methyl group at the N-6-position of the A(2A)-AdoR selective 2-pyrazolyladenosine analogues (Figure 2) brought about a substantial increase in the A(3)-AdoR binding affinity and selectivity. While the N-6-desmethyl analogues 3a and 4 were inactive at the A(3)AdoR (K-i > 10,muM), the corresponding N-6-methyl analogues 5 and 22 showed good binding affinity at the A(3)-AdoR (K-i = 73 and 97 nM, respectively). Replacement of the carboxamide group in 5 with different heteroaryl groups resulted in analogues with high affinities and selectivity for the A(3)-AdoR. (2R,3S,4R)-tetrahydro-2-(hydroxymethyl)-5-(6-(methylamino)-2-(4-(pyridin-2-yl)-1H-pyrazol-1-yl)-9H-purin-9-yl)furan-3,4-diol (15, Ki = 2 nM) displayed high selectivity for the A(3)-AdoR versus A(1)- and A(2A)-AdoRs (selectivity ratios of 1900 and >2000, respectively).

  DOI：

  10.1021/jm049682h

文献信息

• REAGENTS AND METHODS FOR SIRTUIN CAPTURE
  申请人：SAUVE Anthony A.

  公开号：US20130065248A1

  公开（公告）日：2013-03-14

  The invention provides a method of preparing a sirtuin complex. The invention also provides a method of detecting a sirtuin in a sample comprising use of the aforesaid sirtuin complex.

  这项发明提供了一种制备sirtuin复合物的方法。该发明还提供了一种检测样品中sirtuin的方法，包括使用上述sirtuin复合物。
• [EN] NOVEL HISTONE METHYLTRANSFERASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS D'HISTONE MÉTHYLTRANSFÉRASES
  申请人：UNIV FREIBURG ALBERT LUDWIGS

  公开号：WO2021053158A1

  公开（公告）日：2021-03-25

  The present invention relates to novel compounds of formula (I) as defined herein. The compounds are inhibitors of histone methyltransferases of the seven-beta-strand family, in particular of KMT9.

  本发明涉及式(I)定义的新的化合物。这些化合物是七-β-链家族组蛋白甲基转移酶的抑制剂，特别是KMT9的抑制剂。
• [EN] NEW BORANOPHOSPHATE ANALOGUES OF CYCLIC NUCLEOTIDES<br/>[FR] NOUVEAUX ANALOGUES BORANOPHOSPHATES DE NUCLÉOTIDES CYCLIQUES
  申请人：BIOLOG LIFE SCIENCE INST FORSCHUNGSLABOR UND BIOCHEMICA VERTRIEB GMBH

  公开号：WO2012130829A1

  公开（公告）日：2012-10-04

  The present invention relates to novel boranophosphate analogues of cyclic nucleotides. The invention further relates to the use of such compounds as reagents for signal transduction research or as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and/or as hydrolysis- and oxidation-resistant ligands for affinity chromatography, for antibody production or for diagnostic applications e.g. on chip surfaces and/or as additive for organ transplantation storage solutions.

  本发明涉及新型硼磷酸酯类环核苷酸类似物。该发明进一步涉及将这类化合物用作信号转导研究的试剂或用作调节环核苷酸调控的结合蛋白和同工酶的调节剂，和/或用作亲和层析的水解和氧化抗性配体，用于抗体生产或诊断应用，例如在芯片表面，和/或作为器官移植保存溶液的添加剂。
• COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF
  申请人：WIGEN BIOMEDICINE TECHNOLOGY (SHANGHAI) CO., LTD.

  公开号：US20200190066A1

  公开（公告）日：2020-06-18

  It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators.

  该内容涉及作为自噬调节剂的化合物及其制备和使用方法，具体提供了一类具有通用公式(I)的化合物，或其药用可接受盐，这是一种自噬调节剂，特别是哺乳动物ATG8同源物调节剂。
• [EN] NON-NUCLEOTIDE COMPOSITIONS AND METHOD FOR TREATING PAIN<br/>[FR] COMPOSITIONS NON-NUCLEOTIDIQUES ET PROCEDE DE TRAITEMENT DE LA DOULEUR
  申请人：INSPIRE PHARMACEUTICALS INC

  公开号：WO2005039590A1

  公开（公告）日：2005-05-06

  The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain, such as traumatic pain, neuropathic pain, organ pain and/or pain associated with diseases. The P2X receptor antagonists useful for this invention are non-nucleotide compounds of general Formula I. Compounds of Formula I can be used alone to treat pain. Compounds of Formula I can also be used in conjunction with other therapeutic agents or adjunctive therapies commonly used to treat pain, thus enhancing the therapeutic effect of pain reduction.

  本发明涉及一种治疗疼痛的方法。该方法包括向受试者施用含有有效量P2X受体拮抗剂的药物组合物。本发明的方法对于减轻疼痛，如创伤性疼痛、神经病性疼痛、器官疼痛和/或与疾病相关的疼痛具有用处。本发明中用于该发明的P2X受体拮抗剂是一般式I的非核苷化合物。式I的化合物可以单独用于治疗疼痛。式I的化合物也可以与其他治疗剂或常用于治疗疼痛的辅助疗法结合使用，从而增强减轻疼痛的治疗效果。

表征谱图